193 related articles for article (PubMed ID: 35687221)
1. Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.
Barnes A; Ooi SJ; Lynch KD; Parthasarathy N; Bishara M; Gounder M; Grafton R; Leach P; Bampton P; Sechi A; Ng W; Connor S; van Langenberg D; Mountifield R; Andrews JM
Dig Dis Sci; 2023 Mar; 68(3):889-896. PubMed ID: 35687221
[TBL] [Abstract][Full Text] [Related]
2. Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease.
Deben DS; Wong DR; van Bodegraven AA
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1433-1444. PubMed ID: 35023443
[TBL] [Abstract][Full Text] [Related]
3. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.
de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E
Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Spencer E; Norris E; Williams C; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
[TBL] [Abstract][Full Text] [Related]
5. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
6. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
7. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients.
Gilissen LP; Derijks LJ; Bos LP; Verhoeven HM; Bus PJ; Hooymans PM; Engels LG
Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):705-10. PubMed ID: 15201586
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine: state of the art in inflammatory bowel disease.
Sandborn WJ
Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
[TBL] [Abstract][Full Text] [Related]
10. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
13. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Serpico MR; Maltz R; Crandall W; Bricker J; Dotson JL; Kim SC; Boyle B
J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):341-345. PubMed ID: 29601433
[TBL] [Abstract][Full Text] [Related]
16. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
17. Real-World Use of Azathioprine Metabolites Changes Clinical Management of Inflammatory Bowel Disease.
Wilson L; Tuson S; Yang L; Loomes D
J Can Assoc Gastroenterol; 2021 Jun; 4(3):101-109. PubMed ID: 34056527
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
19. Do clinical and laboratory parameters predict thiopurine metabolism and clinical outcome in patients with inflammatory bowel diseases?
Frick S; Müller D; Kullak-Ublick GA; Jetter A
Eur J Clin Pharmacol; 2019 Mar; 75(3):335-342. PubMed ID: 30610277
[TBL] [Abstract][Full Text] [Related]
20. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
